ATE305041T1 - Kompositionen und verwendungen von cgi-69 - Google Patents

Kompositionen und verwendungen von cgi-69

Info

Publication number
ATE305041T1
ATE305041T1 AT01946702T AT01946702T ATE305041T1 AT E305041 T1 ATE305041 T1 AT E305041T1 AT 01946702 T AT01946702 T AT 01946702T AT 01946702 T AT01946702 T AT 01946702T AT E305041 T1 ATE305041 T1 AT E305041T1
Authority
AT
Austria
Prior art keywords
compositions
cgi
directed
present
methods related
Prior art date
Application number
AT01946702T
Other languages
English (en)
Inventor
David Lewin
Sean H Adams
Xing Xian Yu
Original Assignee
Genentech Inc
Curagen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Curagen Corp filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE305041T1 publication Critical patent/ATE305041T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AT01946702T 2000-06-22 2001-06-22 Kompositionen und verwendungen von cgi-69 ATE305041T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21330700P 2000-06-22 2000-06-22
PCT/US2001/020117 WO2001098355A2 (en) 2000-06-22 2001-06-22 Cgi-69 compositions and methods of use

Publications (1)

Publication Number Publication Date
ATE305041T1 true ATE305041T1 (de) 2005-10-15

Family

ID=22794566

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01946702T ATE305041T1 (de) 2000-06-22 2001-06-22 Kompositionen und verwendungen von cgi-69
AT01950401T ATE276363T1 (de) 2000-06-22 2001-06-22 Metabolismuskontrolle mittels zusamensetzungen des humanen 2-oxoglutarat-trägers

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01950401T ATE276363T1 (de) 2000-06-22 2001-06-22 Metabolismuskontrolle mittels zusamensetzungen des humanen 2-oxoglutarat-trägers

Country Status (7)

Country Link
US (2) US7141421B2 (de)
EP (2) EP1294877B1 (de)
AT (2) ATE305041T1 (de)
AU (4) AU2001271395B2 (de)
CA (2) CA2414033A1 (de)
DE (2) DE60113535T2 (de)
WO (2) WO2001098512A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414033A1 (en) 2000-06-22 2001-12-27 Genentech, Inc. Control of metabolism with compositions of the human 2-oxoglutarate carrier
WO2009035574A1 (en) * 2007-09-10 2009-03-19 Merck & Co., Inc. Method for measuring mitochondrial membrane potential in vertebrate cells
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
CN109629463B (zh) * 2019-01-23 2023-12-08 河南中平交科研究设计院有限公司 一种桥梁端头加固结构及桥梁板端头裂缝处理工艺
CN114837060B (zh) * 2022-03-29 2024-01-12 江苏远方交通勘察设计研究院有限公司 一种桥梁建造工程用安全型临时栈道结构

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
SE9702457D0 (sv) 1997-06-26 1997-06-26 Pharmacia & Upjohn Ab Screening
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
AU4548299A (en) * 1998-06-08 1999-12-30 Trustees Of Boston University Novel methods for identifying modulators of mitochondrial anion carrier activity
AU4992299A (en) 1998-07-14 2000-02-07 Amylin Pharmaceuticals, Inc. Uncoupling protein 4 (ucp-4) and methods of use
WO2000061614A2 (en) * 1999-04-09 2000-10-19 Human Genome Sciences, Inc. Uncoupling proteins
CA2414033A1 (en) 2000-06-22 2001-12-27 Genentech, Inc. Control of metabolism with compositions of the human 2-oxoglutarate carrier

Also Published As

Publication number Publication date
EP1294881B1 (de) 2004-09-15
AU2001268715B2 (en) 2007-01-11
CA2414033A1 (en) 2001-12-27
AU7139501A (en) 2002-01-02
DE60105609D1 (de) 2004-10-21
DE60113535T2 (de) 2006-06-22
EP1294877A2 (de) 2003-03-26
WO2001098355A3 (en) 2002-10-03
AU6871501A (en) 2002-01-02
US7141421B2 (en) 2006-11-28
WO2001098512A3 (en) 2003-01-03
DE60105609T2 (de) 2005-09-22
ATE276363T1 (de) 2004-10-15
EP1294881A2 (de) 2003-03-26
AU2001271395B2 (en) 2007-02-08
WO2001098512A2 (en) 2001-12-27
US20020119137A1 (en) 2002-08-29
DE60105609T8 (de) 2006-02-16
US20020103150A1 (en) 2002-08-01
EP1294877B1 (de) 2005-09-21
DE60113535D1 (de) 2006-02-02
WO2001098355A2 (en) 2001-12-27
CA2414065A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
EA200201214A1 (ru) Замещенные тиоацетамиды
TR200300478T2 (tr) Hümanize antiLT-ß-R antikorları
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
BR0113798A (pt) Derivados de resorcinol
EA200400586A1 (ru) Замещённые тиоацетамиды
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
BRPI0414463A (pt) ácidos heteroarilbenzofuránicos substituìdos
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
MXPA03010158A (es) Sulfonamidas.
NO20031860L (no) Kahalalid F
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
SE9904674D0 (sv) Novel compounds
DE60101559D1 (de) Benutzung von comt-inhibitoren als analgetika
BR0110577A (pt) Decorina transgenicamente produzida
DE60113535D1 (de) Kompositionen und verwendungen von cgi-69
ATE557034T1 (de) Identifikation von epitopen und erniedrigung der allergenität von nahrungsmittelproteinen
TR200401875T2 (tr) Endoparazit öldürücü bileşimler
ATE455579T1 (de) Sojaprodukte enthaltende zusammensetzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties